CNS 7056: a novel ultra-short-acting Benzodiazepine

Area of Science:

• Pharmacology
• Neuroscience

Background:

• Development of CNS 7056, a novel benzodiazepine derivative.
• Goal: achieve superior sedative profile (predictable onset, short duration, rapid recovery).
• Achieved through esterase-susceptible metabolism.

Purpose of the Study:

• Evaluate the in vitro and in vivo profile of CNS 7056.
• Assess binding affinity and selectivity for benzodiazepine receptors.
• Determine sedative effects and mechanism of action.

Main Methods:

• Radioligand binding assays for affinity and selectivity.
• Whole-cell patch clamp for GABAA receptor subtype activity.
• In vivo electrophysiology in rats for brain receptor activity.
• Rodent loss of righting reflex test for sedative effects.

Main Results:

• CNS 7056 exhibits high affinity for benzodiazepine sites; metabolite CNS 7054 has lower affinity.
• Enhanced gamma-aminobutyric acid (GABA) currents via GABAA receptor subtypes.
• No clear selectivity among GABAA receptor subtypes observed.
• Induced dose-dependent, short-duration sedation in rodents, reversible by flumazenil.

Conclusions:

• CNS 7056 is a potent sedative acting on the GABAA receptor's benzodiazepine site.
• Demonstrates rapid onset and short duration of action in vivo.
• Mechanism involves brain benzodiazepine receptors, as evidenced by electrophysiology and flumazenil antagonism.